Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents

Journal of Clinical Microbiology

Volumn 51, Issue 8, 2013, Pages 2728-2731

  Mendes, Rodrigo E ^a   Deshpande, Lalitagauri M ^a   Kim, Jihye ^b   Myers, Debra S ^b   Ross, James E ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; RIBOSOME RNA; RIFAMPICIN; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; CENTRAL VENOUS CATHETER; DEATH; ENDOCARDITIS; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LEFT VENTRICULAR ASSIST DEVICE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS SANGUINIS;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; COINFECTION; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; MALE; MUTATION, MISSENSE; OXAZOLIDINONES; PHENOTYPE; POINT MUTATION; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 84880621555     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00757-13     Document Type: Article

References (21)

1. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. Antimicrob. Agents Chemother. 57:1077-1081.
2. Pfizer. 2010. Zyvox package insert. Pfizer Inc., New York, NY. http://www.pfizer.com/products/rx/rx-product-zyvox.jsp.
3. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70.
4. Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV, Arias CA. 2012. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob. Agents Chemother. 56:3917-3922.
5. Bozdogan B, Appelbaum PC. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23:113-119.
6. Long KS, Vester B. 2012. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob. Agents Chemother. 56: 603-612.
7. Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.
8. Mutnick AH, Enne V, Jones RN. 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37: 769-774.
9. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. CLSI document M07-A9. CLSI, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. CLSI document M100-S23. CLSI, Wayne, PA.
11. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. 2010. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J. Antimicrob. Chemother. 65:2329-2335.
12. Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ. 2012. Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob. Agents Chemother. 56:332-340.
13. Meka VG, Gold HS. 2004. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39:1010-1015.
14. Miller K, Dunsmore CJ, Fishwick CW, Chopra I. 2008. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob. Agents Chemother. 52:1737-1742.
15. McCoy LS, Xie Y, Tor Y. 2011. Antibiotics that target protein synthesis. Wiley Interdiscip. Rev. RNA 2:209-232.
16. Polacek N, Mankin AS. 2005. The ribosomal peptidyl transferase center: structure, function, evolution, inhibition. Crit. Rev. Biochem. Mol. Biol. 40:285-311.
17. Kannan K, Mankin AS. 2011. Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann. N. Y. Acad. Sci. 1241:33-47.
18. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. 2004. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48:3169-3171.
19. Long KS, Poehlsgaard J, Hansen LH, Hobbie SN, Bottger EC, Vester B. 2009. Single 23S rRNA mutations at the ribosomal peptidyl transferase centre confer resistance to valnemulin and other antibiotics in Mycobacterium smegmatis by perturbation of the drug binding pocket. Mol. Microbiol. 71:1218-1227.
20. Billal DS, Feng J, Leprohon P, Legare D, Ouellette M. 2011. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 12:512.
21. Wyeth Pharmaceuticals Inc. 2005. Tygacil package insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA.